Latest news

• Roche reports continued growth in Q3, despite biosimilar competition

  In Europe, sales were down 1% thanks to the competition from biosimilars for Herception and Rituxan, but there was growth reported in the uptake of Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra.

• Pfizer’s Talzenna cleared for breast cancer in Europe

  Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).

• Pfizer gets EU nod for Tagrisso rival Vizimpro

  Roche’s Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).

• Pfizer claims rapid FDA nod for Lorbrena

  Lorbrena can also be used in patients who have seen disease progression on Roche’s Alecensa and Novartis’ Zykadia.

• Ocrevus surge keeps Roche smiling in Q3

  However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led